...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Promissory Note

Would really like to know what's going on with Zenith regarding a buyout...we've heard discussion on this for a long time....any rumors on something during 2021?

Would Zenith fetch over $10.00 per share on competitive bidding...we've had no negative information on Zenith and cancer related drugs are in vogue now...any thoughts or comments?

Share
New Message
Please login to post a reply